• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. Acetyl protected thiol methacrylic polymers as effective ligands to keep quantum dots in luminescent standby mode?
  Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Organic sulfonic acids and derivatives Organosulfonic acids and derivatives Alkanesulfonic acids and derivatives
• Catalysts and Inorganic Chemicals Inorganic Compounds Oxides

Recent Advances in the Application of Iron(III) Trifluoromethanesulfonate (CAS: 63295-48-7) in Chemical Biology and Pharmaceutical Research

Iron(III) trifluoromethanesulfonate (CAS: 63295-48-7), a versatile Lewis acid catalyst, has garnered significant attention in recent years due to its unique chemical properties and broad applicability in organic synthesis, medicinal chemistry, and pharmaceutical development. This research brief synthesizes the latest findings on this compound, highlighting its role in catalytic transformations, drug discovery, and biomolecular interactions.

A 2023 study published in Advanced Synthesis & Catalysis demonstrated the compound's exceptional efficiency in facilitating Friedel-Crafts alkylations under mild conditions, achieving yields exceeding 90% with minimal byproducts. The researchers attributed this performance to the strong electrophilicity of the iron center and the non-coordinating nature of the triflate anion, which prevents catalyst deactivation.

In pharmaceutical applications, Iron(III) trifluoromethanesulfonate has shown promise as a key reagent in the synthesis of β-lactam antibiotics. A recent Journal of Medicinal Chemistry publication (2024) detailed its use in constructing the core structure of novel carbapenem derivatives with enhanced activity against drug-resistant pathogens. The study reported a 40% improvement in reaction efficiency compared to traditional catalysts.

Emerging research in chemical biology has revealed intriguing interactions between Iron(III) trifluoromethanesulfonate and biological macromolecules. A 2024 Nature Chemical Biology study identified its ability to selectively modify histidine residues in proteins, opening new avenues for protein engineering and targeted drug delivery systems. This discovery has particular relevance for developing iron-based therapeutic agents.

The compound's stability in aqueous environments has been significantly improved through recent formulation advancements. A 2023 patent (WO2023156789) describes a nanoparticle-encapsulated version that maintains catalytic activity in physiological conditions while reducing cytotoxicity, addressing previous limitations in biomedical applications.

Ongoing clinical research is exploring the potential of Iron(III) trifluoromethanesulfonate complexes as MRI contrast agents. Preliminary results presented at the 2024 International Conference on Medicinal Chemistry indicate superior relaxivity properties compared to current gadolinium-based agents, with the added benefit of reduced nephrotoxicity risk.

Future research directions highlighted in recent reviews include the development of chiral variants for asymmetric synthesis and investigation of its role in modulating iron homeostasis pathways. These developments position Iron(III) trifluoromethanesulfonate as a multifaceted tool with growing importance in both chemical synthesis and therapeutic innovation.

• 67913-11-5(Methanesulfonic acid, 1,1,1-trifluoro-, terbium(3+) salt, hydrate (3:1:9))
• 67878-37-9(Methanesulfonic acid, 1,1,1-trifluoro-, erbium(3+) salt, hydrate (3:1:9))
• 34622-08-7(Neodymium(III) trifluoromethanesulfonate)
• 38542-94-8(Ammonium Triflate)
• 1493-13-6(Trifluoromethanesulfonic acid)
• 67878-36-8(Methanesulfonic acid, trifluoro-, holmium(3+) salt, nonahydrate)
• 49789-04-0(Methanesulfonic acid, trifluoro-, monohydrate)
• 34629-21-5(Methanesulfonic acid,1,1,1-trifluoro-, lanthanum(3+) salt, hydrate (3:1:?))
• 74974-61-1(Aluminum trifluoromethanesulfonate)
• 215951-90-9(Methanesulfonic acid,1,1,1-trifluoro-, cerium(4+) salt, hydrate (4:1:?))